Novo Nordisk Stock Plunges After Disappointing Obesity Drug Data

Shares of the pharmaceutical giant plummeted 20% after a late-stage weight loss drug trial missed expectations.

Johanna Englundh 20 December, 2024 | 12:36PM
Facebook Twitter LinkedIn

Novo Nordisk flags

Shares in Danish drug maker Novo Nordisk (NOVO B), known for its blockbuster drugs Ozempic and Wegovy, fell roughly 20% on Friday after it released the results of a clinical trial for the experimental obesity drug CagriSema.

CagriSema helped patients lose an average of 22.7% of their body weight in a late-stage trial, missing the goal for an average of 25% weight loss. The result was only marginally better than the average weight loss of 20.2% of Zepbound, a rival treatment from Eli Lilly LLY. Eli Lilly stock rose following the news.

The phase 3 study included around 3,400 people with a BMI above 30 or BMI above 27 combined with some weight-related morbidity.

Analysts at Berenberg concluded in a survey in late September that if CagriSema is equivalent to Zepbound’s figure of 20% average weight loss, the share price reaction would be hard to predict, with a share price reaction in this scenario ranging from -20% to +5%. The market reacted even stronger initially, but recovered the fall slightly to -20% about an hour after the news.


The author or authors do not own shares in any securities mentioned in this article. Find out about Morningstar's editorial policies.

The information contained within is for educational and informational purposes ONLY. It is not intended nor should it be considered an invitation or inducement to buy or sell a security or securities noted within nor should it be viewed as a communication intended to persuade or incite you to buy or sell security or securities noted within. Any commentary provided is the opinion of the author and should not be considered a personalised recommendation. The information contained within should not be a person's sole basis for making an investment decision. Please contact your financial professional before making an investment decision.

Facebook Twitter LinkedIn

About Author

Johanna Englundh  Johanna Englundh is an editor for Morningstar in Sweden 

© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures